Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
europe top stories
5
×
life sciences
5
×
national blog main
clinical trials
europe blog main
fda
national top stories
boston blog main
boston top stories
national
san francisco top stories
new york top stories
roche
san francisco blog main
abaloparatide
abbvie
alkermes
allergan
amgen
arena pharmaceuticals
billy dunn
biogen
biopharma
boston
boulder/denver blog main
boulder/denver top stories
buprenorphine
cancer
cardiovascular disease
cariprazine
colorectal cancer
deals
detroit blog main
detroit top stories
drug prices
drug pricing
duchenne
eisai
eli lilly
What
medicine
5
×
drug
fda
approval
marketing
patients
roche
therapy
weight
won
alkermes
amgen
amgen’s
antipsychotic
approved
atrophy
benefits
betting
billion
biopharma
cancer
carries
caveats
commonly
daily
deal
designed
developed
duchenne
effect
eisai
europe
european
evrysdi
favor
flags
friday
gain
gene
green
Language
unset
Current search:
medicine
×
" life sciences "
×
" europe top stories "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning